Objective To systematically evaluate the clinical efficacy and safety of alendronate sodium tablets combined with atorvastatin in the treatments of diabetes with osteoporosis . Methods According to search for the CNKI, VIP, Wanfang, PubMed, the Cochrane library and Embase database, and find out the basic plans of alendronate sodium that combined with atorvastatin were used to treat diabetes with bone Randomized Controlled Trials (RCTs) of Clinical Porosity. Then used the Stata14.0 software to analyze the included literatures. Results A total of 10 RCT literatures and 937 subjects were included, there are 471 in the observation group and 466 in the control group. Meta-analysis results showed that: compared with alendronate sodium tablets that combined with atorvastatin calcium in the treatments of diabetes and osteoporosis, the bone mineral density (BMD) changes in the lumbar spine SMD was 0.38 (0.25, 0.51) ), femoral neck SMD was 0.55 (0.42, 0.68), femoral tuberosity SMD was 0.54 (0.41, 0.67), forearm SMD was 0.45 (0.32, 0.58), All of them were significant statistically. It could also reduce the pain score, SMD is -3.07 (-3.90, -2.23), there was no statistical difference in RR of various adverse reactions. Conclusion Compared with alendronate sodium tablets that combined with atorvastatin as the basic regimen in the treatment of diabetes with osteoporosis, it can improve the clinical efficacy and reduce adverse reactions |